FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 356:2445-2448 June 14, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Audio Interview Perspective by Longmore, G. D. Perspective by Steinbrook, R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Longmore, G. D. Related Article by Steinbrook, R. PubMed Citation

On May 10, 2007, the Food and Drug Administration (FDA) convened a meeting of its Oncology Drug Advisory Committee to discuss concerns about risks associated with the erythropoiesis-stimulating agents (ESAs) used to treat anemia caused by chemotherapy. The principal ESAs under scrutiny were epoetin alfa (Procrit, Eprex, and Epogen) and darbepoetin alfa (Aranesp), and the risks — actual or potential — were thromboembolic disease, promotion of tumor growth, and decreased survival. The actual risk of thromboembolic events was shown in two phase 3 clinical trials, reported in the Journal in 2006, that unequivocally showed an increased risk of death or . . . [Full Text of this Article]

Source Information

Dr. Khuri is a professor and the section head of hematology and medical oncology at the Emory Winship Cancer Institute, Atlanta.

An interview with James Doroshow, director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, can be heard at www.nejm.org.

Related Letters:

Erythropoietins in Oncology
Lattanzi S. C., Khuri F. R.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1262-1263, Sep 20, 2007. Correspondence

This article has been cited by other articles:

• Jadersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., Hellstrom-Lindberg, E. (2008). Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. JCO 26: 3607-3613 [Abstract] [Full Text]  
• May, K. A., Khuri, F. R. (2008). Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion. Cancer Res. 68: 4013-4017 [Abstract] [Full Text]  
• Fandrey, J. (2008). Erythropoietin Receptors on Tumor Cells: What Do They Mean?. The Oncologist 13: 16-20 [Abstract] [Full Text]  
• Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., Fornarini, G., Pozzi, P., Fabi, A., Labianca, R., Di Costanzo, F., Secondino, S., Crucitta, E., Apolloni, F., Del Santo, A., Siena, S. (2008). Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. JCO 26: 1619-1625 [Abstract] [Full Text]  
• Dubsky, P., Sevelda, P., Jakesz, R., Hausmaninger, H., Samonigg, H., Seifert, M., Denison, U., Mlineritsch, B., Steger, G., Kwasny, W., Stoger, H., Bartsch, R., Stierer, M., Taucher, S., Fridrik, M., Schippinger, W., Greil, R., Potter, R., Gnant, M., for the Austrian Breast and Colorectal Cancer Stud, (2008). Anemia Is a Significant Prognostic Factor in Local Relapse-Free Survival of Premenopausal Primary Breast Cancer Patients Receiving Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil Chemotherapy. Clin. Cancer Res. 14: 2082-2087 [Abstract] [Full Text]  
• Shankar, A. G. (2008). The Role of Recombinant Erythropoietin in Childhood Cancer. The Oncologist 13: 157-166 [Abstract] [Full Text]  
• Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Rarick, M. U., Regan, D. H., Lichtin, A. E. (2008). Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. JCO 26: 132-149 [Abstract] [Full Text]  
• May, K. A., Khuri, F. R. (2008). Role of Erythropoietin-stimulating Agents in the Outcomes of Patients with Cancer. Am Soc Clin Oncol Ed Book 2008: 140-144 [Abstract] [Full Text]  
• Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Rarick, M. U., Regan, D. H., Lichtin, A. E. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111: 25-41 [Abstract] [Full Text]  
• Lattanzi, S. C., Khuri, F. R. (2007). Erythropoietins in Oncology. NEJM 357: 1262-1263 [Full Text]  
• Murphy, N. F., McDonald, K. (2007). Treatment of anaemia in chronic heart failure optimal approach still unclear. Eur Heart J 28: 2185-2187 [Full Text]